{
  "pmcid": "12416893",
  "sha256": "88457d7d9de7d54fec95cc9561b1603c2ca68cc3b1b1be429ed192117e971992",
  "timestamp_utc": "2025-11-09T15:40:41.467379+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.616467366499318,
    "reading_ease": 31.155867944621946,
    "word_count": 313
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "This study examined the effect of 2 and 4 mg/kg sugammadex compared to spontaneous recovery of neuromuscular block on the recovery of the acute hypoxic ventilatory response (AHVR)."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This was a two-experiment, randomized, controlled trial in healthy volunteers."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants received a continuous infusion of rocuronium, to achieve stable symptoms of neuromuscular block in the head and neck region (symptomatic neuromuscular block). Thereafter, neuromuscular block was allowed to recover spontaneously in the first experiment, while in experiment 2, volunteers were randomized to receive 2 mg/kg or 4 mg/kg sugammadex for reversal."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study examined the effect of 2 and 4 mg/kg sugammadex compared to spontaneous recovery of neuromuscular block on the recovery of the acute hypoxic ventilatory response (AHVR)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "AHVR was measured at baseline, during stable neuromuscular block, and at 0, 20, and 40 min after recovery."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "volunteers were randomized to receive 2 mg/kg or 4 mg/kg sugammadex for reversal."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 37 volunteers were enrolled; data from 27 volunteers were eligible for analysis."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "data from 27 volunteers were eligible for analysis."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "AHVR was reduced by 32% (mean difference vs. baseline, –0.22 l · % −1 · min −1 ; 95% CI, –0.32 to –0.12) during symptomatic neuromuscular block (mean train-of-four ratio, 0.42 ± 0.22;)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}